The acute haemodynamic effect of nebulised frusemide in stable, advanced heart failure
Heart, Lung, and Circulation, 05/18/2012Newton PJ et al.
This study showed that nebulised frusemide had no significant clinical effect on the haemodynamic characteristics of the subjects.
In this randomised, double blind, placebo controlled trial.
People with stable, advanced heart failure undergoing right heart catheterisation were randomised to receive either 40mg (4ml) of nebulised frusemide or 4ml of normal saline.
Following inhalation of the study medication, subjects’ pulmonary pressures were recorded every 15min for 1h.
There were no significant changes in the weighted average time course data of the subjects (n=32) in either group over the study period, in particular no differences were observed in haemodynamic parameters between the two groups.
Weighted average pulmonary capillary wedge pressure after 60min in the frusemide group was 22.5 (SD 6.5) mmHg (n=14) compared to the placebo group's 24.0 (SD 7.3) mmHg (n=18), p=0.55.
The frusemide group had a significantly greater change in the median volume of urine in the bladder over the study period (186ml IQR 137.8–260.8) compared to the placebo group (76ml IQR 39.0–148.0) p=0.02.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.